Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

Jorge Labrador, Elisa Luno, Edo Vellenga, Salut Brunet, Jose Gonzalez-Campose, Maria C. Chillon, Aleksandra Holowiecka, Jordi Esteve, Juan Bergua, Jose D. Gonzalez-Sanmiguel, Cristina Gil, M. Tormo, Olga Salamero, Felix Manso, Isolda Fernandez, Javier de laSerna, Maria-Jose Moreno, M. Perez-Encinas, Isabel Krsnik, Josep-Maria RiberaJose Cervera, Maria J. Calasanz, Blanca Boluda, Marta Sobas, Bob Lowenberg, Miguel A. Sanz, Pau Montesinos*, L. Palmer, Fernandez, S. Ciarlo, F. Bezares, F. Rojas, H. Longoni, M. Gelemur, P. Fazio, C. Canepa, S. Saba, G. Balladares, P. Negri, M. Giunta, J. Milone, M. Prates, D. Lafalse, C. Sossa, F. Jaramillo, J. Mayer, F. Ramos, J. Martinez, M. R. de Groot, H. C. Schouten, Programa Español de Tratamientos en Hematología (PETHEMA) group, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Polish Adult Leukemia Group, PALG, Grupo Argentino de Tratamiento de la Leucemia Aguda, GATLA

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1146-1155
Number of pages10
JournalLeukemia & Lymphoma
Volume60
Issue number5
DOIs
Publication statusPublished - 16 Apr 2019

Keywords

  • Acute promyelocytic leukemia
  • complex karyotype
  • ATRA
  • chemotherapy
  • prognostic
  • relapse
  • TRANS-RETINOIC ACID
  • ADDITIONAL CHROMOSOME-ABNORMALITIES
  • RISK-ADAPTED TREATMENT
  • ARSENIC TRIOXIDE
  • ANTHRACYCLINE MONOCHEMOTHERAPY
  • PROGNOSTIC-SIGNIFICANCE
  • CONSOLIDATION THERAPY
  • CYTOGENETIC CHANGES
  • FLT3 MUTATIONS
  • PETHEMA

Cite this